Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Revenue (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Revenue data on record, last reported at $9.2 million in Q4 2025.

  • For Q4 2025, Revenue rose 223.77% year-over-year to $9.2 million; the TTM value through Dec 2025 reached $30.9 million, up 36.75%, while the annual FY2025 figure was $30.9 million, 36.75% up from the prior year.
  • Revenue reached $9.2 million in Q4 2025 per FHTX's latest filing, up from $8.2 million in the prior quarter.
  • Across five years, Revenue topped out at $17.5 million in Q3 2023 and bottomed at $41000.0 in Q3 2021.
  • Average Revenue over 5 years is $5.4 million, with a median of $5.5 million recorded in 2023.
  • Peak YoY movement for Revenue: plummeted 77.09% in 2021, then soared 16080.49% in 2022.
  • A 5-year view of Revenue shows it stood at $713000.0 in 2021, then surged by 486.82% to $4.2 million in 2022, then soared by 37.88% to $5.8 million in 2023, then crashed by 50.49% to $2.9 million in 2024, then soared by 223.77% to $9.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $9.2 million in Q4 2025, $8.2 million in Q3 2025, and $7.6 million in Q2 2025.